-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $80

Benzinga·08/25/2026 12:53:45
Listen to the news
JP Morgan analyst Anupam Rama maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $75 to $80.